Allen Klee, an analyst from Maxim Group, reiterated the Buy rating on WELL Health Technologies Corp. The associated price target remains the same with C$8.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Allen Klee has given his Buy rating due to a combination of factors that highlight WELL Health Technologies Corp’s strong performance and strategic focus. The company reported better-than-expected results for the second quarter, which has positively influenced its financial outlook. Additionally, WELL Health is targeting the upper half of its guidance, indicating confidence in its operational capabilities.
Furthermore, the company’s plan to divest its US business and concentrate on its Canadian operations is seen as a strategic move to streamline its focus and resources. This decision is expected to enhance its profitability and operational efficiency. As a result, Allen Klee has raised the EBITDA estimates for WELL Health, reinforcing the Buy rating with a price target of C$8.
According to TipRanks, Klee is an analyst with an average return of -15.1% and a 28.63% success rate. Klee covers the Technology sector, focusing on stocks such as Castellum, Roadzen Inc, and Health In Tech, Inc. Class A.
In another report released yesterday, RBC Capital also maintained a Buy rating on the stock with a C$7.00 price target.